Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors
The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.
The Award reinforces Cadila’s digital initiatives which is backed by innovation, research & development and robust frameworks.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Subscribe To Our Newsletter & Stay Updated